Call for Abstracts

Abstract Submission is closed. Thank you for your submission.
Abstract Result Notification will be sent to the first author in mid-December, 2015.

Open: June 1, 2015
Deadline: October 15, 2015
  November 11, 2015   *No further extension!!

General Guidelines

  • Abstract title must be limited to 255 characters.
  • The body of abstracts should contain a maximum of 2,000 characters and must be submitted in English.
  • No chart and graphics should be included in the abstract.
  • All confirmed abstracts will be published on the ICHG application and webpages.
  • The first author must present his/her presentation.
  • The first author must make a pre-registration when submitting an abstract.
  • The first author who cannot make a pre-registration due to some unavoidable reasons must inform the secretariat in advance.
  • Abstract submissions will only be accepted via the congress website.

ID and Password

  • After registering your abstract, you will receive a confirmation by e-mail with your login ID and password codes.
  • If you do not receive any confirmation by e-mail please contact the Program Secretariat: prog-ichg2016@congre.co.jp.
    Note: We cannot inform you of your password and ID for security reasons. Please print out the website after your registration.
  • If you wish to make any corrections to an abstract already submitted or wish to delete your abstract, you should use your personal ID and password.
  • If your submitted abstract is accepted we will contact you with details about the time about presentation around December.
  • If you have any questions regarding the Abstract Submission, please contact the Program Secretariat. (prog-ichg2016@congre.co.jp)

Attention

  • Abstract Submission Number and Password are generated automatically when an abstract is submitted. During the submission period, you may edit your abstract with this ID number and the password. Please retain them for future reference.
  • For security purposes, Program Secretariat will not answer any questions related to the submission number and password.
  • The first author is responsible for getting agreements from co-authors before submission.
  • After the submission period, change of abstract and addition and/or change of authors cannot be made. Please make sure all authors are entered.
  • Any submitted abstracts will not be edited or proof-read before printing. The first author is responsible for his/her abstract.

Abstract topic and subtopic (2 required)

Please choose 2 most appropriate topics for your abstract

1. Bioinformatics and Genomic Technology
a Novel bioinformatics/computational tools and methods
b Improvements on existing bioinformatics/computational tools or updated versions
c Use of existing bioinformatic methods for novel discovery
d Methods/tools for variant calling in human genomes
e Genome sequencing and assembly
f Methods for data integration
g Model organism genomics
h Technology advancement
i Other
2. Cancer Genetics
a Analysis of candidate genes/regions and fine mapping
b Cancer epidemiology and genome-wide association studies
c Functional studies of associated variants or loci
d Genetic markers of diagnosis, prognosis and/or response to therapy
e Animal models of inherited cancer and predisposition
f Chromosomal instability and DNA repair abnormalities
g Sequencing/somatic mutations or somatic cancer genetic studies
h Chromosomal and other large-scale genomic changes in cancer
i Clinical description, prognosis, and treatment of known cancer syndromes
j Epigenetic changes in cancer
k New cancer susceptibility syndromes
l Other
3. Cardiovascular Genetics
a Candidate genes/regions and fine mapping
b Description of new syndromes
c Diagnostic methods
d Functional studies of associated variants or loci
e Gene–environment interactions
f Genome-wide association studies
g Pathway and system biology approaches
h Sequencing studies/rare variants
i Other
4. Clinical Genetics and Dysmorphology
a Chromosomal disorders
b Contiguous gene/microdeletion disorders
c Multiple congenital anomaly disorders
d Single gene/mendelian disorder
e Other
5. Clinical Genetic Testing
a Demonstration of new laboratory technology in/for a clinical setting
b Laboratory experiences regarding genetic/genomic testing/screening
c New testing/screeing technologies
d Utilization of clinical testing/screening
e Other
6. Complex Traits and Polygenic Disorders
a Whole exome/genome sequencing studies/rare variants
b Candidate genes/regions and fine mapping
c Functional studies of associated variants or loci
d Model systems of complex disease or gene interactions
e Missing heritability
f Genome-wide association studies
g Replication of susceptibility genes/alleles
h Gene/environment interactions
i Pathway network/system genetics analyses of traits/diseases
j Integration of linkage/IBD and association methods
k Joint application of statistical and molecular methods
l Use of Biobanks and EHRs
m Other
7. Cytogenetics
a Chromosome structure
b Copy number/structural genomic variation
c Cytogenetic studies
d Molecular cytogenetic technologies (eg, FISH, microarrays, etc.)
e Other
8. Development
a Ciliopathies
b Developmental origins of adult disease
c Model organism
d Neural crest migration
e Other
9. Epigenetics
a DNA methylation
b Histone modification
c Imprinting
d Twin studies
e X-inactivation
f Other
10. Ethical, Legal, Social and Policy Issues in Genetics
a Data sharing and privacy issues
b Informed consent
c Policy, legal and regulatory issues
d Return of genetic test results
e Social and cultural implications of genetic and genomic technologies
f Other
11. Evolutionary and Population Genetics
a Admixture and ancestry analysis
b Comparative genomics
c Linkage disequilibrium/recombination
d Molecular evolution
e Mutation and polymorphism
f Natural selection and adaptation
g Population history and relationships
h Population isolates and founder mutations
i Rare variants
j Other
12. Genetic Counseling
a Counseling and communication strategies
b Decision making
c Family history
d Psychosocial responses and adaptation to genetic testing
e Risk assessment and risk perception
f Stakeholder preferences and attitudes
g Other
13. Genetics/Genomics Education
a Continuing/professional
b Graduate and medical
c Primary and secondary education (K-12)
d Public
e Undergraduate
f Other
14. Genome structure, variation and function
a Transcription regulation
b Non-coding RNA
c Posttranscriptional regulation/RNA editing
d Transcriptomic/proteomic signatures
e Genomic responses in differentiation, disease, stress or stimulation
f Microbiomes
g Chromatin characteristics/nuclear organization
h Copy number variation
i Descriptive analyses of sequence variation
j Expression quantitative trait locus (eQTL) studies
k Other
15. Health Services Research
a Access to care
b Clinical utility and translation of new technologies
c Economic outcomes
d Genetic service delivery models and tool
e Outcomes research
f Other
16. Metabolic Disorders
a Biochemical basis of disease
b Characterization of new disorders
c Diagnostic methods
d Molecular basis of an inborn error
e Natural history of known disorders
f Newborn screening
g Treatment of metabolic disease
h Other
17. Molecular Basis of Mendelian Disorders
a Animal models and phenotype synthesis
b Linkage/candidate genes/regions
c Targeted/whole exome/genome sequencing studies
d Hematopoietic/immunologic defects
e Renal/genitourinary defects
f Endocrinological defects
g Biochemical characterization
h Phenotype-directed functional characterization
i Gastrointestinal disorders
j Neurogenetic disorders
k Skeletal disorders
l Other
18. Pharmacogenetics
a Candidate genes/regions and fine mapping
b Functional studies of associated variants or loci
c Genome-wide association studies
d Implementation of individualized medicine
e Pharmacodynamics
f Pharmacokinetics
g Sequencing studies/rare variants
h Small molecule screening and in vitro
i Other
19. Prenatal, Perinatal and Reproductive Genetics
a Assisted reproductive technologies
b Fetal imaging
c Genetic screening
d Gynecologic complications
e Infertility
f Maternal serum screening
g Preimplantation diagnosis
h Prenatal diagnosis
i Preterm birth
j Other
20. Psychiatric Genetics, Neurogenetics and Neurodegeneration
a Candidate genes/regions and fine mapping
b Genome-wide association studies
c Sequencing studies/rare variants
d Development
e Diagnostic methods
f Functional studies of associated variants or loci
g Gene-environment interactions
h Neuroimaging genetics
i Phenotypic definitions and subphenotyping
j Predictors of progression and response to treatment
k Tandem repeats, triplet expansions and disease
l Other
21. Statistical Genetics and Genetic Epidemiology
a Aggregate/Burden Association Methods for Rare Variants
b Statistical analysis programs/software
c Analysis of risk, genotype/phenotype, penetrance and individual variants association methods
d Study Design, Quality control, Pre-Processing, Population Stratification adjustments
e Family based association, identity-by-descent, linkage or segregation methods
f Pathway, network, Systems Analysis, Gene x Gene and Gene x Environment Anayses
g Other
22. Therapy for Genetic Disorders
a Drug treatments
b Enzyme replacement therapy
c Gene therapy
d RNAi therapies
e Other

CLOSED

Program Secretariat of the 13th International Congress of Human Genetics
c/o Congress Corporation,
Kohsai-kaikan Bldg., 5-1 Kojimachi, Chiyoda-ku, Tokyo 102-8481, Japan
Phone: +81-3-5216-5318   Fax: +81-3-5216-5552
E-mail: prog-ichg2016@congre.co.jp

PAGE TOP